Britain's AstraZeneca launches $1 billion China investment fund with CICC

SHANGHAI (Reuters) - AstraZeneca said it is lauching a new fund with China International Capital Corporation (CICC) to invest $1 billion (£777.00 million) in China's healthcare sector, as it expands its research work in the country. The fund would look to invest in Chinese firms, with companies in a life-sciences park it helped open in the eastern city of Wuxi last year to be among its first beneficiaries, the British drugmaker's chief executive officer, Pascal Soriot, told Reuters.

Reuters November 06, 2019 05:07:22 IST
Britain's AstraZeneca launches $1 billion China investment fund with CICC

Britains AstraZeneca launches 1 billion China investment fund with CICC

SHANGHAI (Reuters) - AstraZeneca said it is lauching a new fund with China International Capital Corporation (CICC) to invest $1 billion (£777.00 million) in China's healthcare sector, as it expands its research work in the country.

The fund would look to invest in Chinese firms, with companies in a life-sciences park it helped open in the eastern city of Wuxi last year to be among its first beneficiaries, the British drugmaker's chief executive officer, Pascal Soriot, told Reuters.

AstraZeneca was a minority partner in the fund and would mainly play an advisory role in selecting investments and supporting the firms, he said. The companies did not disclose financial details of the deal.

"It's a substantial investment on our side, but also our financial partners," Soriot said of the agreement, to be signed with the Chinese investment bank CICC on the sidelines of the China International Import Expo on Wednesday.

"We can help choose some of those investments but we can also help along the way the startup companies, develop products and find their way around the world" he said, describing it as AstraZeneca's largest-scale healthcare industrial fund.

The company also planned to expand an existing research and development centre in Shanghai from 450 employees to 1,000, and establish a new artifical intellgience innovation centre in the city.

Western drugmakers have profited from partnerships in China, where AstraZeneca's sales have doubled since 2012, as well as a softening in the regulatory environment for pharmaceutical firms.

But the government has also been trying to slash drug prices, changing the playing field as many firms had relied in the past on selling older drugs at premium prices. In September, China also expanded a pilot bulk-buying programme to the entire country in an attempt to negotiate lower prices from drug manufacturers.

Soirot said these were both factors in AstraZeneca's decision to make those investments in China, as the price pressures were encouraging companies to create new drugs that the government was approving and reimbursing at a faster pace.

AstraZeneca, he said, wanted to start making drugs it could export globally from China. Areas of opportunity included oncology and respiratory diseases.

"Historically, until today, our Chinese team has been developing global products for the Chinese market. We want now the Chinese team to take the global leadership on some projects," he said.

(Reporting by Brenda Goh; Editing by Stephen Coates)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Global Markets: Stocks ascend to record on economic recovery, vaccine outlook
Business

Global Markets: Stocks ascend to record on economic recovery, vaccine outlook

By Chuck Mikolajczak NEW YORK (Reuters) - A gauge of global stocks hit a record and oil prices jumped on Monday as the newest positive data for a potential COVID-19 vaccine and signs of economic recovery in Asia boosted sentiment. U.S. stocks advanced, with the Dow Industrials setting a record as it neared the 30,000 mark for the first time, after pharma company Moderna said its prospective vaccine was 94.5% effective in preventing the illness, which has crushed economies across the globe

Airbnb IPO filing shows third-quarter earnings beating virus with cost cuts, new focus
Business

Airbnb IPO filing shows third-quarter earnings beating virus with cost cuts, new focus

By Anirban Sen and Joshua Franklin (Reuters) - Airbnb Inc's initial public offering (IPO) registration showed on Monday that the home rental startup turned a profit in the third quarter despite the COVID-19 pandemic, as it gears up for one of the most anticipated stock market debuts in recent years. The filing, published ahead of Airbnb's anticipated stock market debut in December, showed a dramatic recovery in its fortunes, after the coronavirus outbreak dragged down its core home rental business during the first half of the year. The slump forced it to lay off 25% of its workforce in May, suspend marketing activities for the year and seek $2 billion (£1.5 billion) emergency funding from investors, including Silver Lake and Sixth Street Partners, at a valuation of $18 billion

Biden says U.S., allies need to set global trade rules to counter China's influence
Business

Biden says U.S., allies need to set global trade rules to counter China's influence

By David Lawder WASHINGTON (Reuters) - U.S. President-elect Joe Biden said on Monday the United States needed to negotiate with allies to set global trading rules to counter China's growing influence but declined to say whether he would join a new China-backed Asian trade pact signed on Sunday.